These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 26330260)

  • 1. Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety.
    Reichel A; Lienau P
    Handb Exp Pharmacol; 2016; 232():235-60. PubMed ID: 26330260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo rat PK profiling in drug discovery: new challenges.
    Zonzini L; Bianchi F; Cesari N; Sartori M
    Expert Opin Drug Discov; 2010 Nov; 5(11):1031-7. PubMed ID: 22827743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating human ADME properties, pharmacokinetic parameters and likely clinical dose in drug discovery.
    Lucas AJ; Sproston JL; Barton P; Riley RJ
    Expert Opin Drug Discov; 2019 Dec; 14(12):1313-1327. PubMed ID: 31538500
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimizing DMPK Properties: Experiences from a Big Pharma DMPK Department.
    Sohlenius-Sternbeck AK; Janson J; Bylund J; Baranczewski P; Breitholtz-Emanuelsson A; Hu Y; Tsoi C; Lindgren A; Gissberg O; Bueters T; Briem S; Juric S; Johansson J; Bergh M; Hoogstraate J
    Curr Drug Metab; 2016; 17(3):253-70. PubMed ID: 26651977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics.
    Fan J; de Lannoy IA
    Biochem Pharmacol; 2014 Jan; 87(1):93-120. PubMed ID: 24055064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modern in vivo pharmacokinetic paradigm: combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery.
    Li C; Liu B; Chang J; Groessl T; Zimmerman M; He YQ; Isbell J; Tuntland T
    Drug Discov Today; 2013 Jan; 18(1-2):71-8. PubMed ID: 22982770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
    Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
    Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
    J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data.
    Heimbach T; Lakshminarayana SB; Hu W; He H
    AAPS J; 2009 Sep; 11(3):602-14. PubMed ID: 19707878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
    Reichel A
    Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.
    Poulin P; Jones HM; Jones RD; Yates JW; Gibson CR; Chien JY; Ring BJ; Adkison KK; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Ku MS
    J Pharm Sci; 2011 Oct; 100(10):4050-73. PubMed ID: 21523782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics/pharmacodynamics model-supported early drug development.
    Chen B; Dong JQ; Pan WJ; Ruiz A
    Curr Pharm Biotechnol; 2012 Jun; 13(7):1360-75. PubMed ID: 22201585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory translational modeling approach in drug development to predict human brain pharmacokinetics and pharmacologically relevant clinical doses.
    Kielbasa W; Stratford RE
    Drug Metab Dispos; 2012 May; 40(5):877-83. PubMed ID: 22287668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens.
    Aljayyoussi G; Kay K; Ward SA; Biagini GA
    Malar J; 2016 Jul; 15(1):344. PubMed ID: 27388207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-based Target Pharmacology Assessment (mTPA): An Approach Using PBPK/PD Modeling and Machine Learning to Design Medicinal Chemistry and DMPK Strategies in Early Drug Discovery.
    Chen EP; Bondi RW; Michalski PJ
    J Med Chem; 2021 Mar; 64(6):3185-3196. PubMed ID: 33719432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.